|
시장보고서
상품코드
2055173
리팍시민 시장 : 적응증별, 제형별, 용량별, 환자층별, 최종 사용자별, 제조업체별, 유통 채널별, 지역별Rifaximin Market, By Indication, By Dosage Form, By Strength, By Patient Group, By End User, By Manufacturer Category, By Distribution Channel, By Geography |
||||||
리팍시민 시장은 2026년에 21억 5,000만 달러에 달하고 2033년까지 44억 7,000만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR은 11.0%를 나타낼 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 21억 5,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 11.00% | 예측 금액(2033년) | 44억 7,000만 달러 |
세계 리팍시민 시장은 제약 업계의 중요한 부문으로, 리파마이신 SV를 원료로 한 반합성 항생제를 중심으로 구성되어 있습니다. 이 약제는 전신으로의 흡수가 최소화되어 있으며, 소화관을 표적으로 한 작용을 나타내기 때문에 독자적인 치료 특성을 가지고 있습니다. 리팍시민은 소화관 내에서 거의 흡수되지 않는 광범위 항생제로 작용하며, 여행자 설사, 간성뇌증, 설사형 과민성 대장 증후군(IBS-D) 등 다양한 장 질환의 치료에 특히 효과적입니다.
이 화합물의 작용기전은 세균의 RNA 중합효소에 결합하여 세균의 RNA 합성을 억제함으로써, 유익한 세균은 보존하면서 장내 미생물 군집 내의 병원성 미생물을 효과적으로 제거하는 데 있습니다. 이러한 독특한 약리학적 특성으로 인해 리팍시민은 전 세계 의료진에게 선호되는 치료 옵션으로 자리매김했으며, 선진국 및 신흥국 경제권 전반에서 놀라운 시장 성장을 이끌고 있습니다. 시장에는 정제나 경구 현탁액 등 다양한 제형이 포함되어 있으며, 그 적응증은 여러 치료 분야에 걸쳐 있으며, 지속적인 임상 연구 개발과 규제 당국의 승인을 통해 계속해서 확대되고 있습니다.
시장 역학
세계 리팍시민 시장은 그 성장 궤도를 종합적으로 뒷받침하는 몇 가지 주요 시장 성장 촉진요인에 의해 주도되고 있습니다. 주요 요인으로는 전 세계 위장 질환 유병률 증가, 장 건강에 대한 인식 제고, 그리고 전신 노출 및 내성 발현을 최소화하는 표적형 항생제 요법의 도입 확대 등을 들 수 있습니다. 과민성 대장 증후군, 염증성 장 질환, 간성뇌증 등의 질환 발생률이 증가하는 데다, 이러한 질환에 걸리기 쉬운 고령화 인구가 전 세계적으로 늘어나면서 리팍시민과 같은 효과적인 치료법에 대한 수요가 크게 증가하고 있습니다. 또한, 국제 여행 증가 추세와 이에 따른 여행자 설사증의 위험이 시장 수요를 더욱 부추기고 있는 반면, 의료진은 리팍시민의 우수한 안전성 프로파일과 약물 상호작용이 적다는 점 때문에 이 약물을 점점 더 선호하고 있습니다.
그러나 시장에는 중대한 제약도 존재합니다. 리팍시민이 기존 항생제에 비해 비용이 높다는 점이 지적되며, 이는 가격에 민감한 시장이나 개발도상국에서의 접근성을 제한하고 있습니다. 특허 만료와 이에 따른 제네릭 의약품과의 경쟁은 시장 수익 성장에 있어 지속적인 과제로 남아 있는 반면, 항생제 승인과 관련된 엄격한 규제 요건은 신규 시장 진출기업나 제품 다양화에 걸림돌이 되고 있습니다. 게다가 특정 지역에서 의료진의 인지도가 낮고, 리팍시민이 국소 작용을 하는 데도 불구하고 항생제 내성에 대한 우려가 시장 침투를 계속해서 저해하고 있습니다. 그럼에도 불구하고 시장 상황에는 큰 기회가 존재하며, 특히 비알코올성 지방간염(NASH), 크론병의 유지 요법, 재발성 게실염 예방과 같은 신흥 치료 분야에서 적응증이 확대됨에 따라 그 가능성이 더욱 넓어지고 있습니다. 신규 제제, 병용 요법 및 맞춤형 치료 접근법의 개발은 큰 성장 잠재력을 지니고 있으며, 신흥 시장의 의료비 지출 증가와 정밀 의학에 대한 관심 증대는 리팍시민 제제 시장 확대와 혁신에 유리한 여건을 조성하고 있습니다.
본 보고서의 주요 특징
- 본 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 시장 성장 촉진요인과 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 관한 중요한 분석도 제공합니다.
- 전 세계 리팍시민 시장의 주요 기업 프로파일을 다양한 지표(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략 등)를 바탕으로 소개합니다.
- 본 보고서의 인사이트를 바탕으로, 마케팅 담당자와 기업 경영진은 향후 제품 출시, 제품 라인업 개편, 시장 확대 및 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
- ‘세계 리팍시민 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자들을 대상으로 합니다.
- 이해관계자들은 세계의 리팍시민 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 할 수 있습니다.
목차
제1장 분석 목적 및 전제 조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 리팍시민 시장 : 적응증별(2021-2033년)
제5장 세계의 리팍시민 시장 : 제형별(2021-2033년)
제6장 세계의 리팍시민 시장 : 용량별(2021-2033년)
제7장 세계의 리팍시민 시장 : 환자층별(2021-2033년)
제8장 세계의 리팍시민 시장 : 최종 사용자별(2021-2033년)
제9장 세계의 리팍시민 시장 : 제조업체별(2021-2033년)
제10장 세계의 리팍시민 시장 : 유통 채널별(2021-2033년)
제11장 세계의 리팍시민 시장 : 지역별(2021-2033년)
제12장 경쟁 구도
제13장 애널리스트의 제안
제14장 참고 문헌 및 분석 방법
KTH 26.06.19Rifaximin Market is estimated to be valued at USD 2.15 Bn in 2026 and is expected to reach USD 4.47 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.15 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.00% | 2033 Value Projection: | USD 4.47 Bn |
The global rifaximin market represents a critical segment within the pharmaceutical industry, centered around a semi-synthetic antibiotic derived from rifamycin SV that exhibits unique therapeutic properties due to its minimal systemic absorption and targeted gastrointestinal action. Rifaximin operates as a broad-spectrum antimicrobial agent that remains largely unabsorbed in the gastrointestinal tract, making it particularly effective for treating various intestinal conditions including traveler's diarrhea, hepatic encephalopathy, and irritable bowel syndrome with diarrhea (IBS-D).
The compound's mechanism involves binding to bacterial RNA polymerase, thereby inhibiting bacterial RNA synthesis and effectively eliminating pathogenic microorganisms within the gut microbiome while preserving beneficial bacteria. This distinctive pharmacological profile has positioned rifaximin as a preferred therapeutic option among healthcare professionals globally, driving substantial market growth across developed and emerging economies. The market encompasses various formulations including tablets and oral suspensions, with applications spanning multiple therapeutic areas that continue to expand through ongoing clinical research and regulatory approvals.
Market Dynamics
The global rifaximin market is propelled by several key drivers that collectively sustain its growth trajectory, primarily including the rising prevalence of gastrointestinal disorders worldwide, increasing awareness about gut health, and growing adoption of targeted antibiotic therapies that minimize systemic exposure and resistance development. The expanding incidence of conditions such as irritable bowel syndrome, inflammatory bowel disease, and hepatic encephalopathy, coupled with an aging global population more susceptible to these ailments, creates substantial demand for effective treatment options like rifaximin. Additionally, the growing trend of international travel and associated risks of traveler's diarrhea further amplifies market demand, while healthcare providers increasingly prefer rifaximin due to its favorable safety profile and minimal drug interactions.
However, the market faces significant restraints including the high cost of rifaximin compared to conventional antibiotics, which limits accessibility in price-sensitive markets and developing economies. Patent expirations and subsequent generic competition pose ongoing challenges to market revenue growth, while stringent regulatory requirements for antibiotic approvals create barriers for new entrants and product variations. Furthermore, limited awareness among healthcare professionals in certain regions and concerns about antibiotic resistance, despite rifaximin's localized action, continue to impede market penetration. Nevertheless, substantial opportunities exist within the market landscape, particularly through expanding applications in emerging therapeutic areas such as non-alcoholic steatohepatitis (NASH), Crohn's disease maintenance therapy, and prevention of recurrent diverticulitis. The development of novel formulations, combination therapies, and personalized treatment approaches presents significant growth potential, while increasing healthcare expenditure in emerging markets and growing emphasis on precision medicine create favorable conditions for market expansion and innovation in rifaximin-based therapeutics.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global rifaximin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include leading Salix Pharmaceuticals, Bausch Health Companies Inc, Alfasigma SpA, Lupin Limited, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Cipla Limited, Teva Pharmaceutical Industries Ltd, Cosmo Pharmaceuticals NV, Zambon Company SpA, Granules India Limited, Alembic Pharmaceuticals Limited, Macleods Pharmaceuticals Limited, MSN Laboratories Pvt Ltd, and Hetero Drugs
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global rifaximin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global rifaximin market
Market Segmentation
- Indication Insights (Revenue, USD Bn, 2021 - 2033)
- Hepatic Encephalopathy (HE)
- Irritable Bowel Syndrome with Diarrhea (IBS-D)
- Traveler's Diarrhea
- Small Intestinal Bacterial Overgrowth (SIBO)
- Inflammatory Bowel Disease-Associated Diarrhea (IBD-D)
- Clostridioides difficile-Associated Diarrhea (adjunct use)
- Other Gastrointestinal Infections
- Dosage Form Insights (Revenue, USD Bn, 2021 - 2033)
- Tablet
- Oral Suspension
- Strength Insights (Revenue, USD Bn, 2021 - 2033)
- 200 mg
- 400 mg
- 550 mg
- Patient Group Insights (Revenue, USD Bn, 2021 - 2033)
- Adult
- Geriatric
- Pediatric
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Gastroenterology Clinics
- Ambulatory Surgical Centers
- Academic and Research Institutes
- Home Healthcare Providers
- Manufacturer Category Insights (Revenue, USD Bn, 2021 - 2033)
- Branded
- Generic
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Salix Pharmaceuticals
- Bausch Health Companies Inc
- Alfasigma SpA
- Lupin Limited
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma Limited
- Cipla Limited
- Teva Pharmaceutical Industries Ltd
- Cosmo Pharmaceuticals NV
- Zambon Company SpA
- Granules India Limited
- Alembic Pharmaceuticals Limited
- Macleods Pharmaceuticals Limited
- MSN Laboratories Pvt Ltd
- Hetero Drugs
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Rifaximin Market, By Indication
- Global Rifaximin Market, By Dosage Form
- Global Rifaximin Market, By Strength
- Global Rifaximin Market, By Patient Group
- Global Rifaximin Market, By End User
- Global Rifaximin Market, By Manufacturer Category
- Global Rifaximin Market, By Distribution Channel
- Global Rifaximin Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Rifaximin Market, By Indication, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hepatic Encephalopathy (HE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Irritable Bowel Syndrome with Diarrhea (IBS-D)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Traveler's Diarrhea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Small Intestinal Bacterial Overgrowth (SIBO)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Inflammatory Bowel Disease-Associated Diarrhea (IBD-D)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Clostridioides difficile-Associated Diarrhea (adjunct use)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other Gastrointestinal Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Rifaximin Market, By Dosage Form, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Tablet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Oral Suspension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Rifaximin Market, By Strength, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- 200 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- 400 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- 550 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Rifaximin Market, By Patient Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Rifaximin Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Gastroenterology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Academic and Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Home Healthcare Providers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Rifaximin Market, By Manufacturer Category, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Rifaximin Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Rifaximin Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturer Category, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturer Category, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturer Category, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturer Category, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturer Category, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Manufacturer Category, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Salix Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bausch Health Companies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alfasigma SpA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cosmo Pharmaceuticals NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zambon Company SpA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Granules India Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alembic Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Macleods Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- MSN Laboratories Pvt Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hetero Drugs
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
